MARKET

MXCT

MXCT

Maxcyte
NASDAQ
0.8169
-0.0264
-3.13%
After Hours: 0.8350 +0.0181 +2.22% 19:37 05/11 EDT
OPEN
0.8300
PREV CLOSE
0.8433
HIGH
0.8435
LOW
0.8092
VOLUME
334.65K
TURNOVER
--
52 WEEK HIGH
2.469
52 WEEK LOW
0.6434
MARKET CAP
87.51M
P/E (TTM)
-1.9482
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MXCT last week (0504-0508)?
Weekly Report · 14h ago
Weekly Report: what happened at MXCT last week (0427-0501)?
Weekly Report · 05/04 09:16
Weekly Report: what happened at MXCT last week (0420-0424)?
Weekly Report · 04/27 09:17
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO effective May 1
PUBT · 04/22 20:45
Weekly Report: what happened at MXCT last week (0413-0417)?
Weekly Report · 04/20 09:16
Weekly Report: what happened at MXCT last week (0406-0410)?
Weekly Report · 04/13 09:17
MaxCyte CFO Parmeet Ahuja files initial beneficial ownership statement (Form 3)
Reuters · 04/10 20:45
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
TipRanks · 04/07 10:45
More
About MXCT
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Webull offers MaxCyte Inc stock information, including NASDAQ: MXCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MXCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MXCT stock methods without spending real money on the virtual paper trading platform.